[
  {
    "ts": "2026-01-29T01:50:00+00:00",
    "headline": "Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.",
    "summary": "Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.",
    "url": "https://www.fool.com/investing/2026/01/28/miss-out-eli-lilly-glp-1-stock-bargain-buy-amgen/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "72261e37-79a4-3156-adff-231dd1be9418",
      "content": {
        "id": "72261e37-79a4-3156-adff-231dd1be9418",
        "contentType": "STORY",
        "title": "Missed Out on Eli Lilly? This GLP-1 Stock Could Be a Bargain Buy.",
        "description": "",
        "summary": "Amgen may not have an approved GLP-1 treatment just yet, but that could change in the future.",
        "pubDate": "2026-01-29T01:50:00Z",
        "displayTime": "2026-01-29T01:50:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/b14fe782cab24ef947fce46c4572e9b5",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A group of business people talking outside.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/wnQGWxAjUP_RumiFWWHD4A--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/b14fe782cab24ef947fce46c4572e9b5.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/j.iK9zNtYOI_ImHtY8p5HA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/b14fe782cab24ef947fce46c4572e9b5.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2026/01/28/miss-out-eli-lilly-glp-1-stock-bargain-buy-amgen/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/missed-eli-lilly-glp-1-015000794.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T04:51:00+00:00",
    "headline": "Ivonescimab Included in FirstWord Pharma's \"The Drugs That Will Shape 2026\"",
    "summary": "Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled \"Spotlight On: The Drugs That Will Shape 2026\", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026 and beyond. Akeso/Summit Therapeutics' ivonescimab(PD-1/VEGF bispecific antibody) was selected for inclusion. It stands as the only drug on this list originating f",
    "url": "https://finance.yahoo.com/news/ivonescimab-included-firstword-pharmas-drugs-045100394.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "7138ac13-77de-342f-850e-85642fe943dc",
      "content": {
        "id": "7138ac13-77de-342f-850e-85642fe943dc",
        "contentType": "STORY",
        "title": "Ivonescimab Included in FirstWord Pharma's \"The Drugs That Will Shape 2026\"",
        "description": "",
        "summary": "Akeso, Inc. (9926.HK) is pleased to share that the international industry media FirstWord Pharma released its list titled \"Spotlight On: The Drugs That Will Shape 2026\", providing an in-depth analysis of 20 key drugs poised to define the trajectory of the global pharmaceutical industry and transform disease treatment paradigms in 2026 and beyond. Akeso/Summit Therapeutics' ivonescimab(PD-1/VEGF bispecific antibody) was selected for inclusion. It stands as the only drug on this list originating f",
        "pubDate": "2026-01-29T04:51:00Z",
        "displayTime": "2026-01-29T04:51:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/404d53d9469a85a6976f0a83cabf16da",
          "originalWidth": 16,
          "originalHeight": 16,
          "caption": "Cision",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/NogZQMYPExLPiqLzU_6Cmw--~B/aD0xNjt3PTE2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/prnewswire.com/404d53d9469a85a6976f0a83cabf16da.cf.webp",
              "width": 16,
              "height": 16,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ycOdVG_6T.cyKwHd.h2oqA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/404d53d9469a85a6976f0a83cabf16da.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/ivonescimab-included-firstword-pharmas-drugs-045100394.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/ivonescimab-included-firstword-pharmas-drugs-045100394.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AKESF"
            },
            {
              "symbol": "SMMT"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "DSKYF"
            },
            {
              "symbol": "NVS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T11:30:00+00:00",
    "headline": "Repertoire速 Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases",
    "summary": "Repertoire速 Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic collaboration with Eli Lilly and Company (\"Lilly\") to develop tolerizing therapies for multiple autoimmune diseases. The collaboration aims to develop treatments that restore immune homeostasis and provide patients with durable remission of their disease without the generalized immune suppression that is c",
    "url": "https://finance.yahoo.com/news/repertoire-immune-medicines-announces-strategic-113000094.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "6e6f61bb-9009-3573-89ab-0dce9621a503",
      "content": {
        "id": "6e6f61bb-9009-3573-89ab-0dce9621a503",
        "contentType": "STORY",
        "title": "Repertoire速 Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases",
        "description": "",
        "summary": "Repertoire速 Immune Medicines, a biotechnology company pioneering the discovery and development of programmable T cell targeted immune medicines, announced today that it has entered a strategic collaboration with Eli Lilly and Company (\"Lilly\") to develop tolerizing therapies for multiple autoimmune diseases. The collaboration aims to develop treatments that restore immune homeostasis and provide patients with durable remission of their disease without the generalized immune suppression that is c",
        "pubDate": "2026-01-29T11:30:00Z",
        "displayTime": "2026-01-29T11:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/ad31fe366f1195db080d6a5a5ba9c12f",
          "originalWidth": 400,
          "originalHeight": 58,
          "caption": "Repertoire Immune Medicines (PRNewsfoto/Repertoire Immune Medicines)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IccUBttaVqx0tteP1xqhqg--~B/aD01ODt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/ad31fe366f1195db080d6a5a5ba9c12f.cf.webp",
              "width": 400,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dMEuQsCHWEH82ZXVmY9rXw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/ad31fe366f1195db080d6a5a5ba9c12f.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/repertoire-immune-medicines-announces-strategic-113000094.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/repertoire-immune-medicines-announces-strategic-113000094.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]